Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

It has been about a month since the last earnings report for Myriad Genetics (MYGN). Shares have lost about ... Following the exact same course, the stock was allocated a grade of D on the value ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

MYGN is on track to process samples for biopharma ... with different disease severity or staging. Cardinal Health’s stock has surged 54% in the past year. Earnings estimates for Cardinal Health ...

Myriad Genetics MYGN is well poised for growth in the coming quarters ... In the past six months, this Zacks Rank #3 (Hold) stock has gained 32.8% compared with a 0.6% rise of the industry and a 20% ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...